

## Dexmedetomidine as adjuvant to Ropivacaine in subarachnoid block for postoperative analgesia in lower limb surgeries.

Dr Rasmi Ranjan Mohanty<sup>1</sup>, Dr Debashree Sahoo<sup>2</sup>, Dr Nibedita Sahu<sup>3</sup>, Dr Ranjita Baksi<sup>4</sup>

<sup>1</sup>Assistant Professor, Department of Orthopaedics, PRM Medical College and Hospital, Baripada

<sup>2,3,4</sup>Assistant Prof. Department of Anaesthesiology, S.C.B Medical College & Hospital, Cuttack

Corresponding author- Dr Ranjita Baksi,

### Abstract

**Background and aim:** Many adjuvants have been used with local anesthetics in spinal anesthesia but none has been found ideal. We have conducted this prospective randomized double blind study to evaluate the effect of intrathecal dexmedetomidine when added to ropivacaine in spinal anesthesia. **Methods:** 50 patients who underwent lower limb surgeries under spinal anesthesia were included in this study and were randomly allocated in to two groups. Group C received intrathecal 3 ml of 0.75% ropivacaine + 0.5 ml normal saline and group D received intrathecal 3 ml of 0.75% ropivacaine + 5 µg dexmedetomidine in 0.5 ml of normal saline. Following intrathecal administration, onset of sensory and motor blockade, maximum dermatomal level achieved, duration of analgesia, hemodynamic parameters and incidence of side effects were observed. **Results:** Onset of sensory and motor block was earlier in group D compared to group C which was statistically significant. Block regression was significantly delayed with the addition of intrathecal dexmedetomidine (Group D) as compared to ropivacaine alone (Group C). Both, time to two segment regressions and time to regression to S2 were delayed significantly in group D. The duration of analgesia was also significantly prolonged in group D (348.00±23.02 min) as compared to group C.(207.60±17.23min) There were no significant difference in haemodynamic parameters and incidence of side effects in both the groups. **Conclusion:** The addition of dexmedetomidine(5 µg) to ropivacaine in spinal anesthesia produces significantly longer sensory and motor blockade along with prolonged postoperative analgesia, without any significant side effects.

**Key words:** Dexmedetomidine, Ropivacaine, Intrathecal, lower limb surgeries.

**Introduction:** Spinal anaesthesia is a commonly used anaesthesia technique for infraumbilical surgeries as it blunts not only the “stress response” to surgery, but also reduces intraoperative blood loss. Bupivacaine is the most commonly used local anesthetic for spinal anaesthesia, however it has cardio and neuro toxic side effects. An enantiomer-specific amide type local anesthetic, ropivacaine, which has lower potential for cardiac and central nervous systemic toxicity was introduced in 1996. It shows greater differentiation between sensory and motor blockade along with improved hemodynamic stability.<sup>1</sup> But its duration of action is limited. Various adjuvants have been used intrathecally to improve the quality and duration of the spinal anaesthesia along with prolonged postoperative analgesia.<sup>2</sup> The most commonly used agents have been opioids, such as morphine, fentanyl and tramadol. However addition of opioids has been associated with unwanted side effects like

respiratory depression, pruritus, nausea and vomiting. Various other drugs such as clonidine, magnesium sulfate, neostigmine, ketamine and midazolam, have also been used but none has been found ideal. Dexmedetomidine, is a novel and highly selective alpha-2 adrenoceptor agonist, have antinociceptive action for both somatic and visceral pain. Various studies have proved the efficacy and safety of intrathecal dexmedetomidine in combination with bupivacaine.<sup>3</sup> But very little data is available in literature on usage of dexmedetomidine with ropivacaine in spinal anaesthesia. Therefore we have done this study to evaluate the effect dexmedetomidine as adjuvant to isobaric ropivacaine in spinal anaesthesia in the patients undergoing lower limb surgeries.

**Methods:** After institutional ethics committee approval this prospective randomised double blind study was conducted on 50 patients. All patients were aged between 18-65 years with ASA grade I or II, posted for lower limb surgeries under spinal anesthesia. This study was conducted in a tertiary care hospital in Odisha from Sept 2021 to Oct 2022. Patients who refused for spinal anesthesia, patients with known history of head injury, psychiatric diseases, patients with known history of allergy to any test drugs and patients suffering from major hepatic, renal or cardiovascular dysfunction, were excluded from the study. Thorough pre-anesthetic evaluation was done and consent was taken and were explained regarding the anesthesia protocol. In operating room they were preloaded with 15 ml/kg of lactated Ringer's solution after putting iv cannula. Noninvasive blood pressure (NIBP), pulse oximeter, electrocardiogram (ECG) were attached to all patients and baseline heart rate, blood pressure and SpO<sub>2</sub> were recorded. Lumbar puncture was performed in L<sub>3</sub>-L<sub>4</sub> or L<sub>4</sub>-L<sub>5</sub> intervertebral space in sitting position through midline approach using 25G Quincke's needle. Patients were randomized on the basis of sealed envelope technique to receive one of the following study drug. **Group C:** 3 ml volume of 0.75% ropivacaine (22.5 mg) and 0.5 ml of normal saline. **Group D:** 3 ml volume of 0.75% ropivacaine (22.5 mg) with 5µg dexmedetomidine in 0.5 ml of normal saline. Study drug was prepared by an anesthesiologist blinded to the study protocol. The anesthesiologist performing the block was blinded to the study drug. The drug was injected intrathecally over 10 to 15 seconds. Immediately after intrathecal injection, patients were then made supine position. The level of sensory block was checked by loss of pinprick sensation by 23 G hypodermic needle and dermatomal levels were tested at every 2 minutes until the highest level of block was achieved. Testing was then conducted every 10 minutes until the time of two segment regression of block and recovery to S<sub>2</sub> dermatome. Motor block was evaluated using the modified Bromage Scale<sup>4</sup> as follows –Bromage 0 - The patient is able to move the hip, knee and ankle. Bromage 1- The patient is unable to move the hip, but is able to move the knee and ankle. Bromage 2- The patient is unable to move the hip, and knee, but is able to move the ankle. Bromage 3- The patient is unable to move the hip, knee, and ankle. Haemodynamic parameters like HR, SBP, DBP and MAP were recorded every 3 minutes after administration of spinal anesthesia for first 15 minutes and subsequently every 5 minutes thereafter. Hypotension was defined as BP below 90 mm Hg or fall more than 20% of base line and was treated with iv fluids and vasopressor (ephedrine 5mg). Any fall in heart rate less than 60 beats was treated with injection atropine 0.6 mg. Highest dermatome level of sensory blockade, the time to reach this level from the time of spinal injection, and time to S<sub>2</sub> sensory regression were

recorded. After commencement of surgery, patients sedation level was evaluated by Modified Ramsay Sedation Score.<sup>5</sup> The incidence of adverse effects such as nausea, vomiting, shivering, itching, pruritus, respiratory depression, sedation and hypotension were recorded. Postoperatively, pain scores was recorded by using Visual Analogue pain scale (VAS).(0= no pain, 10= the most severe pain), initially every 1 hour for 2 hours, every 2 hours for next 8 hours and then after every 4 hours till 24 hours. Injection Paracetamol 1gm iv was given as rescue analgesia when VAS≥4.<sup>6</sup>Power analysis suggested that a sample size of 23 patients per group was required to achieve a power of 80% and a level significance of 0.05 to be able to detect a difference in the mean duration of analgesia by 60 min between the groups. Interpretation of the data was carried out and analyzed using statistical package for social sciences (SPSS version 19, IBM Corp, NY, USA). Data was represented as mean ± standard deviation for continuous data and frequency (percentage) or median (range) for nonparametric (categorical) data. The two groups were compared using analysis of variance. The proportion of adverse effects was compared using Chi-square test.  $P < 0.05$  was considered statistically significant.  $P < 0.001$  was considered highly statistically significant.

**Results:** 50 patients were included in the study. The groups were comparable with respect to demographic characteristics (Table 1).

**Table No -1 Patient’s characteristics**

<b>Variables</b>	<b>Group C</b>	<b>Group D</b>	<b>P value</b>
Age (yrs.)	37.77±12.38	40.76±10.35	0.3547
Sex(M/F)	19/6	17/8	0.7528
Height( cm)	164.16±13.32	159±11.4	0.12
Weight(kg)	59.92±5.41	61.52±6.33	0.3360
ASA Physical status(I/II)	15/10	14/11	0.7528

**Table-2 Comparison of block characteristics**

<b>Block characteristics</b>	<b>Group-C</b>	<b>Group-D</b>	<b>P-value</b>
Onset of sensory block in mins	3.96±1.2	2.98±1.3	<0.001
Onset of motor block in mins	5.2±0.8	4.3±1.2	<0.001
Height of block	T5	T6	>0.001
Time to maximum cephalad spread in mins	12.20±0.829	11.01±0.6	>0.001
Time for two segment	96.81±12.35	122.52±5.32	<0.001

regression in mins			
Time for regression to S2 in mins	186.00±18.87	330.60±22.56	<0.001
Total duration of analgesia in mins	207.60±17.23	348.00±23.02	<0.001

The results regarding the characteristics of sensory as well as motor block are summarized in (Table2). Onset of sensory and motor block was earlier in group D compared to group C which was statistically significant. There was no statistical difference in height of block achieved and time to achieve highest level of block. Block regression was significantly delayed with the addition of intrathecal dexmedetomidine (Group D) as compared to ropivacaine alone (Group C). Both, time to two segment regressions and time to S2 regression were delayed significantly in group D. The duration of analgesia was also significantly prolonged with the addition of dexmedetomidine(348.00±23.02 min) as compared to ropivacaine alone.(207.60±17.23min) There were no serious adverse effects in the any patients. Only 1 patients in group C and 2 patients in group D had hypotension which required treatment with a single dose of 6mg ephedrine. There was no significant difference in side effects in both groups.

**Table No-3 Comparison of adverse effects.**

Side Effects	Group C	Group D	P value
Shivering	5	3	>0.001
Hypotension	1	2	>0.001
Nausea	2	2	>0.001
Vomitting	0	0	>0.001
Bradycardia	1	2	>0.001
Neurological Sequel	0	0	>0.001

**Discussion:** In this study we have tried to evaluate the efficacy and safety of intrathecal dexmedetomidine in combination with ropivacaine.  $\alpha_2$  adrenoceptor agonist like clonidine has been extensively used in anaesthetic practice for their sympatholytic, sedative, analgesic, and anaesthetic-sparing effects.<sup>7</sup> Ropivacaine is a newer amide local anesthetic, which is less toxic to the central nervous system and cardiovascular system and shows rapid recovery of motor function.<sup>8</sup> Hyperbaric ropivacaine produces more predictable and reliable sensory and motor block, with faster onset than a plain solution. Since commercial preparations of hyperbaric ropivacaine are not yet available, adjuvants to isobaric solution are being investigated to prolong the duration of action of plain ropivacaine. Addition of fentanyl, clonidine and dexmedetomidine have been studied to prolong the effect on sensory and motor block duration of bupivacaine.<sup>9-10</sup> In this study we have tried to evaluate the efficacy and hemodynamic stability of intrathecal dexmedetomidine in combination with

isobaric ropivacaine. Dexmedetomidine is a highly selective  $\alpha_2$  agonist with a 10 times greater  $\alpha_2/\alpha_1$  selectivity than clonidine  $\alpha_1$  receptors.<sup>11</sup> Dexmedetomidine has most commonly used as an adjuvant to local anaesthetic agents in regional blocks including in neuraxial blocks. Al-Ghanem et al<sup>12</sup> and Al-Mustafa et al<sup>23</sup> in their studies found that the effect of dexmedetomidine is dose dependent and that the onset of sensory blockade was more rapid and duration is prolonged with the use of dexmedetomidine which was similar to our study. In a study conducted by Kanazi et al<sup>13</sup> they observed that 3  $\mu\text{g}$  dexmedetomidine or 30  $\mu\text{g}$  clonidine added to spinal bupivacaine prolonged the duration of sensory and motor block to same extent with minimal side-effects in urologic surgical patients. Similar findings were observed in our study where we observed that there was a significant prolongation in duration of both sensory as well motor blockade in the group receiving intrathecal dexmedetomidine along with ropivacaine. Similar block characteristics were found by Gupta et al<sup>14</sup> and Gupta et al.<sup>22</sup> The mechanism of action by which spinal alfa-2 adrenoceptor agonist prolongs the motor and sensory block is not well known.<sup>15</sup> The local anaesthetics act by blocking sodium channels, whereas the alfa-2 adrenoceptor agonist acts by binding to pre-synaptic C-fibres and post-synaptic dorsal horn neurons. The analgesic action of intrathecal alfa-2 adrenoceptor agonist is by depressing the release of C-fibre transmitters and by hyperpolarisation of post-synaptic dorsal horn neurons.<sup>16</sup> There may be synergistic effect of action of the local anaesthetic and the alfa-2 adrenoceptor agonist as studied by Salgado et al.<sup>17</sup> which explain the prolongation of sensory block when added to spinal local anaesthetics. Khaw et al<sup>18</sup>, in their study evaluated different doses (10, 15, 20 and 25 mg) of ropivacaine in cesarean section. The effective dose (ED50 and ED95) for spinal ropivacaine was calculated to be 16.7 mg (ED50) and 26.8 mg (ED95). Kessler et al<sup>19</sup>, in their study concluded that isobaric ropivacaine (22.5 mg) was suitable for spinal anesthesia for lower abdominal gynaecological surgery. Various other studies have reported that 5  $\mu\text{g}$  intrathecal dexmedetomidine is safe and devoid of any neurotoxic side effect<sup>20</sup>, hence, we used 5  $\mu\text{g}$  dexmedetomidine along with 22.5mg isobaric ropivacaine (0.75%). In our study there was a significant delay in the time to first rescue analgesia in group receiving intrathecal dexmedetomidine and there was a significant reduction in the analgesic consumption in the first 24 hours. So dexmedetomidine can be effectively and safely used as an intrathecal adjunct to ropivacaine.

### **Conclusion**

Dexmedetomidine when added to ropivacaine intrathecally, provides prolonged sensory and motor blockade, better postoperative analgesia, reduced requirement of rescue analgesic in first 24 hour with minimal side effects in lower limb surgeries.

### **References:**

1. Kehlet H. The stress response to surgery: Release mechanisms and the modifying effects of pain relief. *Acta Chir Scand Suppl* 1988; 550: 22.
2. Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. *BMJ* 2000; 321:1493.

3. Urwin SC, Parker MJ, Griffiths R. General versus regional anaesthesia for hip fracture surgery: a meta-analysis of randomized trials. *Br J Anaesth* 2000; 84(4): 45.
4. Graf BM. The cardiotoxicity of local anesthetics: the place of ropivacaine. *Curr Top Med Chem* 2001; 1(3): 207-14.
5. Marret E, Thevenin A, Gentili M, Bonnet F. Comparison of intrathecal bupivacaine and ropivacaine with different doses of sufentanil. *Acta Anaesthesiol Scand* 2011; 55: 670-6.
6. Schug SA, Saunders D, Kurowski I, Paech MJ. Neuraxial drug administration: a review of treatment options for anaesthesia and analgesia. *CNS Drugs* 2006; 20(11): 917-33.
7. Kalso EA, Poyhia R, Rosenberg PH. Spinal antinociception by dexmedetomidine a highly selective alpha-2 adrenergic agonist. *Pharmacol Toxicol* 1991; 68: 140-3.
8. Hennawy AME, Abd-Elwahab AM, Abd-Elmaksoud AM, El-Ozairy HS and Boulis S R. Addition of clonidine or dexmedetomidine to bupivacaine prolongs caudal analgesia in children. *Br J Anaesth* 2009; 103(2): 268-74.
9. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colino MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. *Anesthesiology* 2000; 93: 382-94.
10. Virtanen R, Savola J-M, Saano V, Nyman L. Characterization of the selectivity, specificity and potency of medetomidine as an  $\alpha_2$ -adrenoceptor agonist. *Eur J Pharmacol* 1988 ;150: 9-14.
11. Eisanach GC, De Kock M, Klimscha W. Alfa-2 adrenergic agonist for regional anaesthesia. *Anesthesiology* 1996; 85: 655-74.
12. Al Ghanem SM, Massad IM, Al-Mustafa MM, Al-Zaben KR, Qudaisat IY, Qatawneh AM, et al. Effect of adding dexmedetomidine versus fentanyl to intrathecal bupivacaine on spinal block characteristics in gynecological procedures: A double blind controlled study. *Am J Appl Sci* 2009; 6: 882-7.
13. Kanazi GE, Aouad MT, Jabbour-Khoury SI, Al Jazzar MD, Alameddine MM, Al-Yaman R, et al. Effect of low dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. *Acta Anaesthesiol Scand* 2006; 50(2): 222-7.
14. Gupta R, Verma R, Bogra J, Kohli M, Raman R, Kushwaha JK. A Comparative study of intrathecal dexmedetomidine and fentanyl as adjuvants to Bupivacaine. *J Anaesthesiol Clin Pharmacol* 2011; 27: 339-43.
15. Harada Y, Nishioka K, Collins JG. Visceral antinociceptive effects of spinal clonidine combined with morphine, enkephalin, or U50, 488H. *Anesthesiology* 1995; 83: 344-52.
16. Yaksh TL, Reddy SV. Studies in primate on the analgesic effects associated with intrathecal actions of opiates, adrenergic agonists and baclofen. *Anesthesiology* 1981; 54: 451-67.
17. Salgado PF, Sabbag AT, Silva PC, Brienze SL, Dalto HP, Modolo NS, et al . Synergistic effect between dexmedetomidine and 0.75% ropivacaine in epidural anesthesia. *Rev Assoc Med Bras* 2008; 54(2): 110-5.

18. Khaw K., Ngan Kee W., Wong E., Liu J., Chung R. Spinal ropivacaine for cesarean section. A dose-finding study. *Anesthesiology* 2001; 95: 1346-1350,
19. Kessler P., Eichler A., Wilke H., Strouhal U., Bremerich D. Intrathecal ropivacaine versus bupivacaine for lower abdominal gynaecological procedures. *Eur. J. Anaesth* 2001; 18, 86, Abs A304.
20. Shukla D, Verma A, Agarwal A, Pandey H. D, Tyagi C. Comparative study of intrathecal Dexmedetomidine with intrathecal Magnesium sulfate used as adjuvants to Bupivacaine. *J Anaesthesiol Clin Pharmacol* 2011; 27(4): 495-9.